Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Pharmacotherapy may achieve diabetes remission
Última actualización 4 de julio de 2026
Key finding
4 out of 14 patients (28.57%) in the intervention arm were in remission.
This study evaluated the effectiveness of pharmacotherapy for achieving diabetes remission. It found that both intervention and control groups had patients in remission, with notable weight loss in the intervention group.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the effectiveness of pharmacotherapy for achieving diabetes remission. It found that both intervention and control groups had patients in remission, with notable weight loss in the intervention group.
Clinical relevance
Achieving diabetes remission can significantly improve patients' quality of life and reduce the risk of diabetes-related complications. Understanding which pharmacotherapy options are effective can guide clinicians in providing better treatment strategies for their patients.
Keep in mind
Small sample size may limit generalizability. Short duration of follow-up may not capture long-term effects. Potential confounding factors not fully controlled.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Anand S, Durairaj A, Shobhit B, et al. Pharmacotherapy targeting tight glycaemic control is effective in achieving diabetes remission. Indian Journal of Endocrinology and Metabolism. 2025;29(2):217-223. doi:10.4103/ijem.ijem_356_24
Efectos Principales
28.57% of participants in the intervention arm achieved diabetes remission.
Weight loss of 4.7 kg was observed in the intervention arm.
BMI decreased by -1.58 kg/m² in the intervention arm.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Liraglutide, Dapagliflozin, and Metformin, Metformin + glimepiride and BMI, Body fat mass, Body fat percentage reduction, and 4 more.
This study contributes evidence to
Primary intervention
Liraglutide, Dapagliflozin, and Metformin
Primary outcomes
- BMI
- Body fat mass
- Body fat percentage reduction
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
14
Evidence pairs
14
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
14
Evidence pairs
131
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 14 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Metformin Therapies and Body Mass Index
Evidencia relacionada
Relación de evidencia
Metformin Therapies and Body Weight
Seguir evidencia
Relación de evidencia
Metformin Therapies and Insulin Resistance
Seguir evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Body fat mass
Liraglutide, Dapagliflozin, and Metformin → Body fat mass
Liraglutide, Dapagliflozin, and Metformin → Body fat mass
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerBody fat percentage reduction
Liraglutide, Dapagliflozin, and Metformin → Body fat percentage reduction
Liraglutide, Dapagliflozin, and Metformin → Body fat percentage reduction
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerBody weight
Liraglutide, Dapagliflozin, and Metformin → Body weight
Liraglutide, Dapagliflozin, and Metformin → Body weight
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerDiabetes remission
Liraglutide, Dapagliflozin, and Metformin → Diabetes remission
Liraglutide, Dapagliflozin, and Metformin → Diabetes remission
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerDisposition Index
Liraglutide, Dapagliflozin, and Metformin → Disposition Index
Liraglutide, Dapagliflozin, and Metformin → Disposition Index
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerInsulin resistance
Liraglutide, Dapagliflozin, and Metformin → Insulin resistance
Liraglutide, Dapagliflozin, and Metformin → Insulin resistance
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerBody fat percentage reduction
Metformin + glimepiride → Body fat percentage reduction
Metformin + glimepiride → Body fat percentage reduction
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerDiabetes remission
Metformin + glimepiride → Diabetes remission
Metformin + glimepiride → Diabetes remission
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerDisposition Index
Metformin + glimepiride → Disposition Index
Metformin + glimepiride → Disposition Index
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerInsulin resistance
Metformin + glimepiride → Insulin resistance
Metformin + glimepiride → Insulin resistance
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerBuild your personal Evidence Workspace
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
La Evidencia Sugiere
- 28.57% remission in intervention group versus 33.33% in control group.
- Weight loss of 4.7 kg in intervention group.
- BMI reduction of -1.58 kg/m² in intervention group.
A quién se aplica
- Adults with type 2 diabetes.
- Patients seeking pharmacotherapy for diabetes management.
Tener en Cuenta
- Results may not apply to all diabetes types.
- Further research needed to confirm long-term effectiveness.
- Findings are based on a specific population with defined characteristics.
Entre Líneas
- Small sample size may limit generalizability.
- Short duration of follow-up may not capture long-term effects.
- Potential confounding factors not fully controlled.
Save this study
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Liraglutide, Dapagliflozin, and Metformin and Body Mass Index, Liraglutide, Dapagliflozin, and Metformin and Body Composition.
Relaciones de evidencia relacionadas
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Detailed evidenceEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Detailed evidenceEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Detailed evidenceEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Body Composition Evidence Hub
All studies measuring Body Composition
1 studies
outcome_hubMeasures Body Composition as a key outcome.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
1 studies
outcome_hubMeasures Body Mass Index as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
Liraglutide, Dapagliflozin, and Metformin Evidence Hub
All studies on Liraglutide, Dapagliflozin, and Metformin
1 studies
intervention_hubContributes to Liraglutide, Dapagliflozin, and Metformin evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en el archivo de evidencia
Jump to pre-filtered views in the evidence archive.
All studies on Liraglutide, Dapagliflozin, and Metformin and BMI
Intervention: Liraglutide, Dapagliflozin, and MetforminOutcome: BMI
1 results
All studies on Liraglutide, Dapagliflozin, and Metformin and Body fat mass
Intervention: Liraglutide, Dapagliflozin, and MetforminOutcome: Body fat mass
1 results
All studies on Liraglutide, Dapagliflozin, and Metformin
Intervention: Liraglutide, Dapagliflozin, and Metformin
1 results
All studies measuring BMI
Outcome: BMI
1 results
All studies measuring Body fat mass
Outcome: Body fat mass
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Metformin Therapies affect body mass index?
Strong Evidence
Metformin Therapies appears to improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies affect body weight?
Strong Evidence
Metformin Therapies appears to improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies improve insulin resistance?
Strong Evidence
Metformin Therapies may improve Insulin Resistance.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Insulin resistance
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies improve body composition?
Moderate Evidence
Metformin Therapies appears to improve Body Composition.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body fat mass
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Body fat percentage reduction
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesMediterranean ketogenic eating matched VLCKD for weight loss over 3 monthsLifestyle calorie-carbohydrate plans improved type 2 diabetes remission versus usual careDietary supplements may lower diabetes risk in prediabetesDigital intervention improves glycemic control in type 2 diabetes patients
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.